Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
1,658
Views
0
CrossRef citations to date
0
Altmetric
Zoster

Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States

Ana Floreaa Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0030-8737View further author information
ORCID Icon,
Lina Sya Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0003-2762-9266View further author information
ORCID Icon,
Lei Qiana Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0001-8001-3992View further author information
ORCID Icon,
Bradley Ackersona Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0002-0816-7345View further author information
ORCID Icon,
Yi Luoa Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0001-8990-2470View further author information
ORCID Icon,
Jun Wua Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0003-3227-4818View further author information
ORCID Icon,
Yanjun Chenga Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0009-0003-3999-1884View further author information
ORCID Icon,
Jennifer Kua Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0001-9469-5875View further author information
ORCID Icon,
Leticia Vega Dailya Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0009-0005-9675-4601View further author information
ORCID Icon,
Harpreet Takhara Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0002-2734-4896View further author information
ORCID Icon,
Jeannie Songa Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAORCID Iconhttps://orcid.org/0009-0006-4349-5885View further author information
ORCID Icon,
Elizabeth Chmielewski-Yeeb Department of Epidemiology and Patient-Centered Outcomes, GSK, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0002-3223-7964View further author information
ORCID Icon,
O’Mareen Spenceb Department of Epidemiology and Patient-Centered Outcomes, GSK, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0003-1573-7809View further author information
ORCID Icon,
Harry Seifertc Department of Clinical Safety and Pharmacovigilance, GSK, Rockville, MD, USAORCID Iconhttps://orcid.org/0000-0001-8048-5885View further author information
ORCID Icon,
Driss Oraichid Department of Real World Analytics, GSK, Rockville, MD, USAORCID Iconhttps://orcid.org/0009-0005-1921-7626View further author information
ORCID Icon &
Hung Fu Tsenga Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA;e Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USAORCID Iconhttps://orcid.org/0000-0001-6184-6534View further author information
ORCID Icon show all
Article: 2327145 | Received 27 Dec 2023, Accepted 02 Mar 2024, Published online: 15 Mar 2024

References

  • Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpää ML, McKendrick MW, et al. Recommendations for the management of Herpes Zoster. Clin Infect Dis. 2007;44(Supplement_1):S1–8. doi:10.1086/510206.
  • Gnann JW Jr., Whitley RJ. Clinical practice: Herpes zoster. N Engl J Med. 2002;347(5):340–346. doi:10.1056/NEJMcp013211.
  • Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26–33. doi:10.1016/S1473-3099(03)00857-0.
  • Centers for Disease Control and Prevention. Shingles (Herpes Zoster); 2020. https://www.cdc.gov/shingles/hcp/clinical-overview.html.
  • Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. Morb Mortal Wkly Rep. 2018;67(3):103–108. doi:10.15585/mmwr.mm6703a5.
  • Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, Kotton CN, Dooling KL. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the advisory committee on immunization practices — United States, 2022. Morb Mortal Wkly Rep. 2022;71:80–84. doi:10.15585/mmwr.mm7103a2.
  • Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. doi:10.1056/NEJMoa1501184.
  • Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. doi:10.1056/NEJMoa1603800.
  • Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study. Clin Infect Dis. 2021;73(6):949–956. doi:10.1093/cid/ciab121.
  • Sun Y, Jackson K, Dalmon CA, Shapiro BL, Nie S, Wong C, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine among Kaiser permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39(29):3974–3982. doi:10.1016/j.vaccine.2021.05.056.
  • Izurieta HS, Wu X, Forshee R, Lu Y, Sung H-M, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis. 2021;73(6):941–948. doi:10.1093/cid/ciab125.
  • Atlas WD. Total population aged 50 and over years; 2020. https://knoema.com/atlas/China/topics/Demographics/Age/Population-aged-50-years.
  • Fei FE, Morten S-K, Heiko JJ, Juan L, Li L, Hongwei G, Zhu X, Preedy V, Lu H, Bohr VA, et al. A research agenda for aging in China in the 21st century. Ageing Res Rev. 2015;24:197–205. doi:10.1016/j.arr.2015.08.003.
  • Dapeng Y, Desirée VO, Ning J, Alen M, Debasish S, Zhenhua W, Tang H, Diaz-Decaro J, Watson P, Xie X, et al. A systematic literature review to assess the burden of herpes zoster disease in China. Expert Rev Anti-Infect Ther. 2021;19(2):165–179. doi:10.1080/14787210.2020.1792290.
  • Li L, Luodan S, Juan L, Xinghuo P. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. J Hum Vaccin Immunother. 2018;14:2632–2635.
  • GlaxoSmithKline. GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over; 2019. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over/.
  • Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/Ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11:100252. doi:10.1016/j.lana.2022.100252.
  • Kim JH, Diaz-Decaro J, Jiang N, Hwang S-J, Choo EJ, Co M, Hastie A, Hui DSC, Irimajiri J, Lee J, et al. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. J Hum Vaccin Immunother. 2021;17(7):2050–2057. doi:10.1080/21645515.2020.1859321.
  • Koebnick C, Langer-Gould AM, Gould MK, Chao CR, Iyer RL, Smith N, Chen W, Jacobsen SJ. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41. doi:10.7812/TPP/12-031.
  • Davis AC, Voelkel JL, Remmers CL, Adams JL, McGlynn EA. Comparing kaiser permanente members to the general population: implications for generalizability of research. Perm J. 2023;27(2):87–98. doi:10.7812/TPP/22.172.
  • European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. 209570 - long-term effectiveness study of Shingrix in adults; 2022. https://www.encepp.eu/encepp/viewResource.htm?id=39740.
  • Tseng HF, Bruxvoort K, Ackerson B, Luo Y, Tanenbaum H, Tian Y, Zheng C, Cheung B, Patterson BJ, Van Oorschot D, et al. The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence. J Infect Dis. 2020;222(5):798–806. doi:10.1093/infdis/jiz652.
  • Langan SM, Smeeth L, Margolis DJ, Thomas SL, Harbarth S. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420. doi:10.1371/journal.pmed.1001420.
  • Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–49. doi:10.1001/jama.2012.7304.
  • Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ. 2000;321(7264):778–779. doi:10.1136/bmj.321.7264.778.
  • Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833.
  • Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, et al. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019;37(43):6262–6267. doi:10.1016/j.vaccine.2019.09.028.
  • Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. J Hum Vaccin Immunother. 2021;17(10):3735–3746. doi:10.1080/21645515.2021.1932216.
  • Harpaz R. The effectiveness of recombinant zoster vaccine: observations in the wild. J Clin Infect Dis. 2021;73(6):957–960. doi:10.1093/cid/ciab130.
  • Nguyen HT, Zheng A, Gugel A, Kistin CJ. Asians and Asian subgroups are underrepresented in medical research studies published in high-impact generalist journals. J Immigr Minor Health. 2021;23(3):646–649. doi:10.1007/s10903-021-01142-6.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.